Oral Session 2-9D Hemolytic anemia

[OS2-9D-1] Safety and Efficacy of the Anti-C1s Antibody BIVV009 in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger¹, Shirley D'Sa², Christian Schörgenhofer¹, Johann Bartko¹, Christian Sillaber¹, Petra Jilma-Stohlawetz¹, Michael Fillitz³, Thomas Schenk⁴, Gary Patou⁵, Sandip Panicker⁵, Graham C. Parry⁵, James C. Gilbert⁶, Bernd Jilma¹ (1.Medical University of Vienna, Vienna, Republic of Austria, 2.University College London Hospitals NHS Foundation Trust & Mount Vernon Cancer Centre, London, United Kingdom of Great Britain and Northern Ireland, 3.Hanusch Krankenhaus, Vienna, Republic of Austria, 4.Universitätsklinikum St. Pölten, St. Pölten, Republic of Austria, 5.Bioverativ Therapeutics Inc., Waltham, United States of America, 6.True North Therapeutics, San Francisco, United States of America)